Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

Tomas Kalincik; Vilija Jokubaitis; Guillermo Izquierdo; Pierre Duquette; Marc Girard; Pierre Grammond; Alessandra Lugaresi; Celia Oreja-Guevara; Roberto Bergamaschi; Raymond Hupperts; Francois Grand'Maison; Eugenio Pucci; Vincent Van Pesch; Cavit Boz; Gerardo Iuliano; Ricardo Fernandez-Bolanos; Shlomo Flechter; Daniele Spitaleri; Edgardo Cristiano; Freek Verheul; Jeannette Lechner-Scott; Maria Pia Amato; Jose Antonio Cabrera-Gomez; Maria Laura Saladino; Mark Slee; Fraser Moore; Orla Gray; Mark Paine; Michael Barnett; Eva Havrdova; Dana Horakova; Timothy Spelman; Maria Trojano; Helmut Butzkueven

Journal article

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

Tomas Kalincik, Vilija Jokubaitis, Guillermo Izquierdo, Pierre Duquette, Marc Girard, Pierre Grammond, Alessandra Lugaresi, Celia Oreja-Guevara, Roberto Bergamaschi, Raymond Hupperts, Francois Grand'Maison, Eugenio Pucci, Vincent Van Pesch, Cavit Boz, Gerardo Iuliano, Ricardo Fernandez-Bolanos, Shlomo Flechter, Daniele Spitaleri, Edgardo Cristiano, Freek Verheul Show all

Multiple Sclerosis Journal | SAGE PUBLICATIONS LTD | Published : 2015

DOI: 10.1177/1352458514559865

Download PDF

University of Melbourne Researchers

Vilija Jokubaitis Author Medicine - Royal Melbourne Hospital

Timothy Spelman Author Surgery - St Vincent's Hospital

John King Author Medicine - Royal Melbourne Hospital

Helmut Butzkueven Author Medicine - Royal Melbourne Hospital

Tomas Kalincik Author Medicine - Royal Melbourne Hospital

Related Projects (4)

Precision Treatment For Multiple Sclerosis: Maximising The Effect Of Immunomodulatory Therapy

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

Treating Progressive Multiple Sclerosis

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

Precision Therapy For Neurological Diseases

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

Selecting Optimal Treatment For Patients With Multiple Sclerosis

Multiple sclerosis is the most common cause of neurological disability among young people. With the increasing choice of therapies, the goal..

Grants

Awarded by Multiple Sclerosis Research Australia Postdoctoral Fellowship

Awarded by NHMRC Early Career Award

Awarded by NHMRC

Awarded by NHMRC Centre for Research Excellence

Funding Acknowledgements

The work was supported by the Multiple Sclerosis Research Australia Postdoctoral Fellowship [11-054] and NHMRC Early Career Award (Clinical) to TK [1071124], NHMRC Career Development Award (Clinical) to HB [628856], NHMRC Project Grant [1032484], NHMRC Centre for Research Excellence [1001216] and the MSBase Foundation. The MSBase Foundation is a not-for-profit organization that receives support from Merck Serono, Biogen Idec, Novartis Pharma, Bayer Schering, Sanofi-Aventis and BioCSL. The study was conducted separately and apart from the guidance of the sponsors. TK had full access to all the data and takes responsibility for integrity of the data and accuracy of the data analysis.